Quantcast

Latest Embryonic stem cell Stories

2014-08-29 23:10:02

For more than a week, Boston’s Adult Stem Cell Technology Center, LLC has been declining offers from participants in the Amyotrophic Lateral Sclerosis (ALS) Ice Bucket Challenge who wish to make donations for research that does not use human embryonic stem cells or tissues derived from aborted fetuses. The company has informed those wishing to donate that its for-profit status prevents it from inviting or receiving charitable donations. Boston, MA (PRWEB) August 29, 2014 Due to a...

2014-08-29 08:24:07

DALLAS, August 29, 2014 /PRNewswire/ -- Launched June 2014, the "Stem Cell Research Products - Opportunities, Tools, and Technologies" market intelligence report supplies research supply companies with the real-time data necessary to make effective product development decisions, sell effectively to scientists, and take market share from the competition. Full-year 2013 analysis determines the size of the stem cell research products market to be $3.22 billion, and the stem cell...

2014-08-27 23:00:26

Upcoming New York Adult Stem Cell Lecture on Wednesday, September 3, 2014, at 2pm and 4pm at the City Limits Diner, at 135 Harvard Avenue, Stamford, CT 06902 New York, California (PRWEB) August 28, 2014 The Manhattan Regenerative Medicine Medical Group announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia M. Smyrniotis, Medical Director....

2014-08-27 08:26:50

Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the...

2014-08-25 08:27:03

- Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business...

2014-08-22 23:05:15

In a new study published in STEM CELLS Translational Medicine on July 14, 2014, researchers from Tokyo Medical and Dental University along with a team from Osaka University may have found a potentially powerful approach for creating human induced pluripotent stem cells (hiPSCs) for clinical use. Durham, NC (PRWEB) August 22, 2014 Human induced pluripotent stem cells (hiPSCs) have great potential in the field of regenerative medicine because they can be coaxed to turn into specific cells;...

2014-08-21 08:28:11

- Welcomes New Shareholders Who Received Series A Shares from Geron Corporation - MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three...

2014-08-14 12:27:58

Computer algorithm also provides 'quality assurance' for lab-created cells BOSTON, Aug. 14, 2014 /PRNewswire-USNewswire/ -- In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable...

2014-08-12 08:30:36

SYDNEY, Aug. 12, 2014 /PRNewswire/ -- The Australian biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD). http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO FSHD is one of the most common forms of muscular dystrophy and genetic hereditary...

2014-08-08 11:20:47

Cell Transplantation Center of Excellence for Aging and Brain Repair Induced immunorejection may eliminate tumors post-cell transplantation Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation. In an...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related